Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.
INTRODUCTION — Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. Urothelial (transitional cell) carcinomas of the renal pelvis account for approximately 8 percent of kidney tumors, and other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare. Nephroblastoma (Wilms' tumor) is common in children (5 to 6 percent of primary renal tumors). (See "Epidemiology, pathology, and pathogenesis of renal cell carcinoma" and "Malignancies of the renal pelvis and ureter".)
An overview of the approach to treatment is presented here; more detailed discussions of specific aspects of treatment are discussed in other topics, as noted below.
GENERAL APPROACH — The initial approach to a patient with presumed renal cell carcinoma (RCC) needs to consider the extent of disease, as well as the patient's age and comorbidity (algorithm 1).
RCC can be classified as:
●Advanced disease – This includes tumor invading beyond Gerota’s fascia or extending into the ipsilateral adrenal gland (T4) and metastatic disease (M1). Either of these findings constitutes stage IV RCC. (See 'Advanced RCC' below.)
An overview of the approach to treatment is presented here; more detailed discussions of specific aspects of treatment are discussed in other topics, as noted below.
LOCALIZED RCC — When patients with renal cell carcinoma (RCC) present with localized disease, definitive therapy can often be curative.
Definitive treatment — Surgery is curative in the majority of patients with RCC who do not have metastases. Surgery is therefore the preferred treatment for patients with stages I, II, and III disease.
Treatment may require a radical nephrectomy, although a partial nephrectomy to preserve renal parenchyma is preferred for appropriately selected patients. The choice of surgical procedure depends upon the extent of disease, as well as patient-specific factors such as age and comorbidity. Surgery may be carried out through a conventional approach or by a minimally-invasive approach such as laparoscopy. (See "Definitive surgical management of renal cell carcinoma".)
In carefully selected patients who present with a resectable primary tumor and a concurrent single metastasis, surgical resection of the metastasis, in conjunction with radical nephrectomy, may be curative. (See "Role of surgery in patients with metastatic renal cell carcinoma".)
Other ablative procedures (eg, cryotherapy, radiofrequency ablation [RFA]) may be an important alternative for patients with relatively small renal masses who are not surgical candidates. (See "Diagnostic approach, differential diagnosis, and treatment of a small renal mass".)
Multiple primary RCCs — Bilateral RCCs are more common among patients with inherited conditions (eg, von Hippel-Lindau disease, tuberous sclerosis, papillary RCC) and occasionally are seen in those with sporadic tumors. In these situations, we recommend surgery. Proper management should include sparing as much renal parenchyma as possible during the initial therapy and monitoring for the development of additional RCCs. (See "Hereditary kidney cancer syndromes" and "Definitive surgical management of renal cell carcinoma", section on 'Partial nephrectomy'.)
Active surveillance — Elderly patients and those with significant comorbidity may not be candidates for surgical resection . Although nonsurgical procedures (eg, cryoablation, RFA) may be useful, most small tumors grow slowly and do not become symptomatic or metastasize [2-6]. In addition, up to 40 percent of tumors smaller than 1 cm in size may be benign . In this setting, observation with periodic reevaluation is a reasonable option. (See "Definitive surgical management of renal cell carcinoma", section on 'Active surveillance' and "Diagnostic approach, differential diagnosis, and treatment of a small renal mass".)
Adjuvant therapy — There is no established role for any type of systemic adjuvant therapy after a complete surgical resection, and the use of adjuvant systemic therapy should be limited to formal clinical trials.
Immunotherapy — The ability of immunotherapy to induce objective tumor responses in some patients with advanced RCCs led to the evaluation of interferon-alfa, interleukin-2, and autologous tumor vaccines as adjuvant therapy following surgical resection. However, multiple randomized trials have not demonstrated a survival benefit from any of these approaches. There are no data on checkpoint inhibitor immunotherapy following resection of high-risk RCC, although phase III studies with T cell checkpoint inhibitors are being planned. (See "Immunotherapy of renal cell carcinoma", section on 'Adjuvant immunotherapy'.)
Antiangiogenic and targeted therapy — Adjuvant therapy with agents targeting the vascular endothelial growth factor (VEGF) pathway has not demonstrated any improvement in overall survival in the adjuvant setting, although these agents can prolong overall survival in patients with metastatic clear cell RCC. (See "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'VEGF TKIs'.)
Three large randomized trials have reported results:
●In the ASSURE trial, 1943 patients with completely resected intermediate-, high-, or very high-risk RCC were randomly assigned to sunitinib, sorafenib, or placebo for up to one year . The primary endpoint of the trial was disease-free survival (DFS).
•There was no improvement in DFS (median 5.8, 6.1, and 6.6 years for sunitinib, sorafenib, and placebo, respectively. For sunitinib versus placebo, hazard ratio [HR] 1.02, 97.5% CI 0.85-1.23; for sorafenib versus placebo, HR 0.97, 97.5% CI 0.80-1.17). There was also no significant difference in overall survival for any of the three treatment arms (for sunitinib versus placebo, HR 1.17, 97.5% CI 0.90-1.52; for sorafenib versus placebo, HR 0.98, 97.5% CI 0.75-1.28).
•Grade 3 or greater toxicity was significantly increased with both sunitinib and sorafenib compared with placebo (hypertension 17 and 16 versus 4 percent, hand-foot syndrome 15 and 33 versus 1 percent, rash 2 and 15 versus <1 percent, and fatigue 18 and 7 versus 3 percent).
●In the PROTECT trial, 1538 patients with completely resected RCC were randomly assigned to pazopanib or placebo . All patients had pT2 grade 3 or 4 disease, pT3 or T4 disease of any grade, or N1 lymph node involvement, and all were free of metastases. Initially, 403 patients were randomized to pazopanib at a dose of 800 mg/day or placebo. The protocol was then amended to starting pazopanib at a dose of 600 mg/day because of an excess risk of hepatoxicity. The amended primary objective of the trial was DFS for patients randomized to the 600 mg/day group or the matching placebo.
Results were presented at the 2017 American Society of Clinical Oncology (ASCO) meeting. The DFS for the 600 mg/day analysis was not statistically different between pazopanib and placebo (three-year rate 67 versus 64 percent, HR 0.94, 95% CI 0.77-1.14). There was a significant difference in those originally assigned to pazopanib 800 mg/day (66 versus 56 percent, HR 0.66, 955 CI 0.49-0.90). Overall survival, a secondary endpoint, will require additional follow-up.
●In the S-TRAC trial, 615 patients with high-risk clear cell RCC were randomly assigned to sunitinib (50 mg/day for four weeks out of each six-week cycle) or to placebo . At a median follow-up of 5.4 years, DFS, the primary endpoint of the trial, was significantly increased in those receiving sunitinib (median 6.8 versus 5.6 years, 59.3 versus 51.3 percent disease free at five years, HR 0.76, 95% CI 0.59-0.95). At the time of data cutoff, data were not mature enough to evaluate overall survival, a secondary endpoint of the trial, although the number of deaths in the two treatment arms was equal. Toxicity was significantly increased with sunitinib compared with placebo, the most common serious side effects being palmar-plantar erythrodysesthesia and hypertension.
Another large phase III trial using girentuximab (an antibody targeting carbonic anhydrase IX) failed to demonstrate any benefit in either DFS or overall survival . The six-year median DFS endpoints of this trial and the ASSURE and S-TRAC trials [8,10] highlight the difficulty of conducting adjuvant trials in patients with high-risk resected RCC in an efficient manner.
Surveillance after resection — Careful surveillance following surgical resection is important to permit early diagnosis of relapse when the tumor burden is limited. The response to therapy of patients who relapse is best in patients with a good performance status and a limited tumor burden. Furthermore, some patients who have a solitary recurrence may be cured with surgical metastasectomy. (See "Surveillance for metastatic disease after definitive treatment for renal cell carcinoma".)
ADVANCED RCC — Many renal cell carcinomas (RCCs) are clinically silent for much of their natural history. Thus, the diagnosis is frequently not made until disease is locally advanced (and unresectable) or has metastasized. In addition, many patients who initially are resectable eventually recur. Systemic therapy (immunotherapy, molecularly targeted agents), surgery, and radiation all may have a role depending upon the extent of disease, sites of involvement, and patient-specific factors.
In general, systemic therapy is initiated promptly when unresectable disease, either metastatic or locally advanced disease, is present. However, for asymptomatic patients with a limited disease burden and no poor prognostic features, close active surveillance may represent an alternative for those wanting to defer the initiation of therapy and its attendant toxicity until more compelling disease progression is documented .
Systemic therapy of clear cell RCC — Immunotherapy (high-dose interleukin-2 [IL-2], nivolumab) and molecularly targeted therapy are the primary systemic modalities for the management of patients whose disease is not controlled by definitive locoregional therapy (table 2 and algorithm 2). The role of immunotherapy in the treatment of RCC and its integration with molecularly targeted therapy as discussed in this topic are consistent with guidelines from the Society for Immunotherapy of Cancer .
•Immunotherapy with high-dose IL-2 is preferred for the initial therapy of advanced clear cell renal cell carcinoma. However, the use of high-dose IL-2 requires access to a center capable of managing the toxicity associated with this treatment regimen and should be limited to patients with a good Karnofsky performance status (KPS; ≥80 percent) (table 3) and intact organ function. IL-2 can induce durable long-term remissions in approximately 10 percent of patients. (See 'Immunotherapy' below and 'Molecularly targeted therapy' below.)
•For patients who are not candidates for high-dose IL-2, antiangiogenic targeted therapy or participation in a protocol involving a PD1 or PDL1 pathway blocker are the primary options. Among the available agents, preferred options for initial therapy include pazopanib and sunitinib. (See 'Molecularly targeted therapy' below.)
•For patients who progress after initial immunotherapy (eg, IL-2 or protocol therapy) we suggest treatment with the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) axitinib rather than sorafenib. For patients without access to axitinib or sorafenib, there are a number of alternative agents that can be administered, including bevacizumab, pazopanib, and sunitinib. (See 'Antiangiogenic (VEGF pathway)' below and "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma".)
•For patients who have progressed after initial treatment with a VEGF pathway inhibitor and who have not received prior immunotherapy, treatment with nivolumab is preferred; cabozantinib is an alternative. Both nivolumab and cabozantinib are superior to the mechanistic target of rapamycin (mTOR) inhibitor everolimus; although these agents have not been directly compared, nivolumab appears to be associated with less toxicity. (See "Immunotherapy of renal cell carcinoma", section on 'Nivolumab' and "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Cabozantinib'.)
●Subsequent therapy – Patients who have progressed following one or two courses of antiangiogenic therapy and immunotherapy may benefit from treatment with an alternative targeted agent. Patients should be encouraged to participate in formal clinical trials whenever possible.
Immunotherapy — Immunotherapy is an important option for the management of patients with advanced clear cell RCC, both as initial therapy (high-dose IL-2) or as secondary therapy after molecularly targeted therapy (nivolumab). (See "Immunotherapy of renal cell carcinoma" and "Principles of cancer immunotherapy".)
Interleukin-2 — Immunotherapy with high-dose bolus IL-2 can activate an immune response against RCC that results in tumor regression in a minority of patients. Although treatment is associated with severe toxicity, responses often persist for many years, even in the absence of additional therapy, and the majority of complete responders remain free of relapse long-term. High-dose IL-2 is an important option for carefully selected patients who are able to tolerate the toxicity associated with this approach and who have access to this treatment. (See "Immunotherapy of renal cell carcinoma", section on 'Interleukin-2'.)
Nivolumab — Nivolumab is an anti-PD-1 antibody that was initially developed for patients with advanced melanoma and non-small cell lung cancer. Initial studies in advanced clear cell RCC showed significant activity in patients who had progressed on or after targeted therapy. In a large phase III trial, nivolumab prolonged overall survival compared with everolimus as second-line therapy in patients progressing after initial treatment with a VEGF TKI, and nivolumab is the preferred option in this setting . Nivolumab was approved by the US Food and Drug Administration (FDA) for patients with advanced renal cell carcinoma whose disease has progressed following antiangiogenic therapy, based upon this trial . (See "Immunotherapy of renal cell carcinoma", section on 'Efficacy of nivolumab'.)
Interferon-alfa — The use of interferon-alpha (IFNa) has largely been replaced by molecularly targeted agents and immunotherapy with high-dose IL-2 or nivolumab. In older trials using a variety of preparations, doses, and schedules, the overall response rate was as high as 15 percent, but most responses were partial and rarely persisted beyond one year. (See "Immunotherapy of renal cell carcinoma", section on 'Interferon-alfa'.)
Molecularly targeted therapy — An understanding of the pathogenesis of RCC at the molecular level has identified the VEGF pathway and mTOR as important targets for therapeutic intervention. (See "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Molecular pathogenesis'.)
Antiangiogenic (VEGF pathway) — Two different approaches have clinical activity in blocking the VEGF pathway (figure 1): the use of small-molecule TKIs (sunitinib, pazopanib, cabozantinib, axitinib, sorafenib) to block the intracellular domain of the VEGF receptor, and a monoclonal antibody (bevacizumab) to bind circulating VEGF and prevent its activating the VEGF receptor . (See "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Inhibitors of the vascular endothelial growth factor (VEGF) pathway'.)
●Randomized clinical trials have demonstrated that VEGF receptor inhibitors prolonged overall survival compared with IFNa for the initial management of advanced RCC and are also active in the treatment of patients with disease progression after cytokine therapy. A randomized clinical trial has also demonstrated that cabozantinib is superior to the mTOR inhibitor everolimus as second-line therapy.
●An alternative approach to interrupting the VEGF pathway uses the anti-VEGF monoclonal antibody, bevacizumab, which has significant activity in combination with IFNa in both untreated patients and those who have failed cytokine therapy.
mTOR inhibitors — The mTOR pathway is downstream of the phosphoinositide 3-kinase and Akt pathway that is regulated by the phosphatase and tensin homolog (PTEN) tumor suppressor gene (figure 1). Inhibition of the mTOR pathway has the potential to inhibit tumor progression at multiple levels. (See "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Inhibitors of the mTOR pathway'.)
However, mTOR inhibitors have a limited role as single agents in advanced RCC. Their principal utility may be in patients whose disease is refractory to initial treatment with VEGF receptor TKIs and/or those patients whose tumors have mutations in the PI3K pathway. Except for this, their use is relegated to fifth- or greater-line therapy in patients whose disease has progressed on multiple VEGF pathway inhibitors, nivolumab, and cabozantinib.
●Temsirolimus – In the four-armed phase II BEST trial of patients who had not received prior targeted therapy, temsirolimus plus either bevacizumab or sorafenib had a worse therapeutic index than either bevacizumab alone or the combination of bevacizumab plus sorafenib . In the INTORSECT trial in patients who had previously been treated with sunitinib, overall survival was significantly worse than with sorafenib . (See "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Bevacizumab' and "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Temsirolimus'.).
●Everolimus – In the RECORD-3 trial, everolimus was inferior to sunitinib as first-line therapy with advanced RCC . In phase III trials in previously treated patients, everolimus was inferior to both nivolumab  and cabozantinib . (See "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Everolimus'.)
Chemotherapy and hormonal therapy — Both chemotherapy and progestational agents had only very limited activity in early studies prior to the development of immunotherapy and molecularly targeted therapy.
●Chemotherapy does not have an established role in the management of patients with advanced or metastatic RCC . A review of early studies reported that fluorinated pyrimidines were the most active agents, but the objective response rate was only 5 to 10 percent .
Subsequent studies with capecitabine and a formulation of the fluorouracil prodrug tegafur have also shown evidence of at least some activity , as have studies with gemcitabine [24-26]. Phase II studies using combinations of gemcitabine plus capecitabine have reported response rates of 8 to 24 percent [27-31], and at least one study has suggested that this combination may be more effective when given in combination with sorafenib . Additional clinical trials will be required to determine whether this approach might have a role in patients who are no longer responsive to immunotherapy or molecularly targeted agents.
●Progestational agents do not have significant antitumor activity. Medroxyprogesterone is the most widely studied. Despite occasional reports of responses, a review of medroxyprogesterone treatment concluded that RCCs are neither hormone-dependent nor hormone-responsive , although some patients with severe anorexia may derive symptomatic benefit from hormonal therapy. (See "Pharmacologic management of cancer anorexia/cachexia", section on 'Progesterone analogs'.)
There is no evidence that other hormonal agents (eg, androgens, antiestrogens, or combinations of hormones and chemotherapy) are effective [34,35].
Combined antiangiogenic plus checkpoint inhibition therapy — The rapid advances in checkpoint inhibition immunotherapy have led to the evaluation of combined immunotherapy plus antiangiogenic therapy. Various combination regiments are currently being evaluated in phase III trials. (See "Immunotherapy of renal cell carcinoma".)
Systemic therapy of non-clear cell carcinoma — The activity of molecularly targeted agents (sunitinib, sorafenib, temsirolimus) in patients with non-clear cell RCC has yet to be evaluated in phase III clinical trials. However, a systematic review and meta-analysis of various phase II and retrospective studies found that these agents have limited activity in patients with non-clear cell RCC, with response rates significantly lower than in clear cell RCC . In addition, treatment with an inhibitor of the MET oncogene may have activity, specifically in papillary RCC . Patients with non-clear cell RCC do not appear to respond to cytokine-based immunotherapy [38,39]. A case report described a dramatic response to nivolumab in a patient with papillary RCC with sarcomatoid features , although confirmatory data are needed before such a treatment approach can be endorsed. (See "The treatment approach to non-clear cell renal carcinoma" and "Immunotherapy of renal cell carcinoma", section on 'Interleukin-2'.)
Subsets of patients with non-clear cell tumors occasionally respond to chemotherapy. Major responses have been reported with various combinations of platinum agents, taxanes, gemcitabine, or ifosfamide in patients with collecting duct tumors [41-44] and sarcomatoid RCCs [45-47]. Renal medullary carcinoma may also be responsive to platinum-based combination chemotherapy regimens [48,49], anthracyclines , or bortezomib [51,52].
Surgery — Most patients with stage IV RCC have unresectable disease and require systemic therapy. However, surgery has a role in the management of some patients.
Radical nephrectomy — For a subset of patients in whom the only evidence of advanced disease is the direct involvement of the ipsilateral adrenal gland, a radical nephrectomy that includes adrenalectomy is potentially curative. (See "Definitive surgical management of renal cell carcinoma", section on 'Adrenal gland involvement'.)
Cytoreductive nephrectomy — Removal of the primary tumor (cytoreductive or debulking nephrectomy) should be performed in all patients when it is clinically feasible and justifiable (good performance status, 75 percent debulking possible, no symptomatic metastatic disease) before initiating systemic therapy. (See "Role of surgery in patients with metastatic renal cell carcinoma", section on 'Nephrectomy'.)
Randomized clinical trials demonstrated that patients who undergo a cytoreductive nephrectomy prior to IFNa immunotherapy had improved survival compared with those with an intact primary tumor [53,54]. Careful patient selection is critical to avoid surgery in patients who will not be able to subsequently receive immunotherapy.
No prospective clinical trial data are available on the merits of cytoreductive nephrectomy in patients who will be treated with VEGF pathway inhibitors or other types of immunotherapy. However, the general consensus is that cytoreductive nephrectomy is indicated in this setting as well.
Metastasectomy — Surgical resection of a single or limited number of metastases is a reasonable option for carefully selected patients. This occasionally is done in conjunction with a radical nephrectomy, but may also be performed following a relapse after surgery. In addition, surgery is sometimes performed to resect residual disease in patients who have had a major but less than complete response to systemic immunotherapy. (See "Role of surgery in patients with metastatic renal cell carcinoma" and "Immunotherapy of renal cell carcinoma".)
Radiation therapy — Although RCC has been characterized as a radioresistant tumor, conventional and stereotactic radiation therapy (RT) are frequently useful to treat a single or limited number of metastases. In these settings, the utility of RT is similar to that in metastases from other tumor types.
Examples of situations where RT is useful include:
●Painful bone metastases (see "Radiation therapy for the management of painful bone metastases")
●Brain metastases (see "Overview of the treatment of brain metastases")
●Painful recurrences in the renal bed
RT has been used as an adjuvant following nephrectomy in patients at high risk for local recurrence [55-57], but its role in this setting remains unproven and is generally discouraged.
SUMMARY AND RECOMMENDATIONS
Localized disease — For patients with a resectable stage I, II, or III renal cell carcinoma (RCC), we recommend surgery as the primary treatment approach (algorithm 1) (Grade 1A). (See "Definitive surgical management of renal cell carcinoma".)
●Radical nephrectomy has been the most widely used approach and remains the preferred procedure when there is evidence of invasion into the adrenal, renal vein, or perinephric fat. (See "Definitive surgical management of renal cell carcinoma", section on 'Radical nephrectomy'.)
●Partial nephrectomy (either open or laparoscopic) is an alternative for smaller tumors and is particularly valuable in patients with bilateral or multiple lesions, those with inherited syndromes in whom there is an increased risk of an additional subsequent primary tumor, and those with impaired renal function. (See "Definitive surgical management of renal cell carcinoma", section on 'Partial nephrectomy'.)
●For elderly patients and those with significant comorbid disease, ablative techniques (cryoablation, radiofrequency ablation) are an alternative. (See "Radiofrequency ablation and cryoablation for renal cell carcinoma".)
●Active surveillance may be an option for patients with small asymptomatic lesions. (See "Definitive surgical management of renal cell carcinoma", section on 'Active surveillance'.)
●Following complete resection of a localized RCC, there is no role for adjuvant therapy with either immunotherapy, vascular endothelial growth factor (VEGF) pathway inhibitors, or mechanistic target of rapamycin (mTOR) inhibitors, except in the context of a formal clinical trial.
Advanced clear cell RCC — The general approach to patients with advanced clear cell RCC is summarized in the table and algorithm (table 2 and algorithm 2 and algorithm 1). (See 'Systemic therapy of clear cell RCC' above.)
●For patients who have a good performance status and intact organ function, we suggest high-dose interleukin-2 (IL-2) rather than antiangiogenic targeted therapy (Grade 2B). (See 'Immunotherapy' above and "Immunotherapy of renal cell carcinoma", section on 'Interleukin-2' and "Immunotherapy of renal cell carcinoma", section on 'Nivolumab'.)
●For patients who will be treated with a molecularly targeted agent, we prefer either pazopanib or sunitinib. (See "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Inhibitors of the vascular endothelial growth factor (VEGF) pathway'.)
●For patients who progress after immunotherapy (IL-2), we suggest axitinib rather than sorafenib (Grade 2B). For patients without access to axitinib or sorafenib, there are a number of alternative agents that could be administered, including bevacizumab, pazopanib, and sunitinib. (See "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Axitinib'.)
●For patients who progress after an initial VEGF pathway inhibitor, we recommend treatment with nivolumab, cabozantinib, or the combination of lenvatinib plus everolimus rather than single agent everolimus (Grade 1B). In this setting, we suggest nivolumab rather than antiangiogenic therapy (Grade 2C). There are no direct comparisons between nivolumab and these alternative approaches, and in phase III trials, nivolumab, cabozantinib, and the combination of lenvatinib plus everolimus had a similar impact on overall survival. However, nivolumab has demonstrated a better safety profile. (See "Immunotherapy of renal cell carcinoma", section on 'Nivolumab' and "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Cabozantinib'.)
Axitinib is also an option and preferred over sorafenib, particularly in patients who have shown some benefit from first line vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapy. Neither nivolumab nor cabozantinib have been compared with axitinib in clinical trials. (See "Anti-angiogenic and molecularly targeted therapy for advanced or metastatic clear-cell renal cell carcinoma", section on 'Axitinib'.)
Treatment beyond the second line
●Patients who have progressed following an initial molecularly targeted agent and immunotherapy may benefit from treatment with an alternative targeted agent. These could include axitinib or cabozantinib rather than everolimus or sorafenib. Patients should be encouraged to participate in formal clinical trials whenever possible.
Advanced non-clear cell RCC
●For patients with non-clear cell RCC, we suggest molecularly targeted therapy rather than chemotherapy (Grade 2C). However, some types of non-clear cell RCC are reported to be chemosensitive (including collecting duct, sarcomatoid, and medullary RCC). (See "The treatment approach to non-clear cell renal carcinoma" and 'Systemic therapy of non-clear cell carcinoma' above.)
- Santos Arrontes D, Fernández Aceñero MJ, García González JI, et al. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 2008; 179:857.
- Lamb GW, Bromwich EJ, Vasey P, Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome. Urology 2004; 64:909.
- Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology 1995; 197:589.
- Volpe A, Panzarella T, Rendon RA, et al. The natural history of incidentally detected small renal masses. Cancer 2004; 100:738.
- Rendon RA, Stanietzky N, Panzarella T, et al. The natural history of small renal masses. J Urol 2000; 164:1143.
- Wehle MJ, Thiel DD, Petrou SP, et al. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology 2004; 64:49.
- Rybicki FJ, Shu KM, Cibas ES, et al. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. AJR Am J Roentgenol 2003; 180:1281.
- Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016.
- Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT) (abstract 4507). 2017 American Society of Clinical Oncology annual meeting.
- Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med 2016.
- Chamie K, Donin NM, Klöpfer P, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol 2016.
- Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 2016.
- Rini BI, McDermott DF, Hammers H, et al. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer 2016; 4:81.
- Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1803.
- Atkins MB. Management of advanced renal cancer. Kidney Int 2005; 67:2069.
- Flaherty KT, Manola JB, Pins M, et al. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol 2015; 33:2384.
- Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32:760.
- Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32:2765.
- Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1814.
- Vogelzang NJ. Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol 2010; 28:5017.
- Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20:303.
- Naito S, Eto M, Shinohara N, et al. Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2010; 28:5022.
- Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1993; 4:331.
- De Mulder PH, Weissbach L, Jakse G, et al. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996; 37:491.
- Casali M, Marcellini M, Casali A, et al. Gemcitabine in pre-treated advanced renal carcinoma: a feasibility study. J Exp Clin Cancer Res 2001; 20:195.
- Chung EK, Posadas EM, Kasza K, et al. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol 2011; 34:150.
- Tannir NM, Thall PF, Ng CS, et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008; 180:867.
- Waters JS, Moss C, Pyle L, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004; 91:1763.
- Stadler WM, Halabi S, Rini B, et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 2006; 107:1273.
- Van Veldhuizen PJ, Hussey M, Lara PN Jr, et al. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol 2009; 32:453.
- Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010; 11:350.
- Kjaer M. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma. Cancer Treat Rev 1988; 15:195.
- Oh WK, Manola J, George DJ, et al. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest 2002; 20:186.
- Stahl M, Wilke H, Schmoll HJ, et al. A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann Oncol 1992; 3:167.
- Vera-Badillo FE, Templeton AJ, Duran I, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol 2015; 67:740.
- Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31:181.
- Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376.
- Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005; 28:488.
- Geynisman DM. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015; 68:912.
- Gollob JA, Upton MP, DeWolf WC, Atkins MB. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 2001; 58:1058.
- Milowsky MI, Rosmarin A, Tickoo SK, et al. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 2002; 94:111.
- Peyromaure M, Thiounn N, Scotté F, et al. Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 2003; 170:1138.
- Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J Urol 2007; 177:1698.
- Rashid MH, Welsh CT, Bissada NK, Chaudhary UB. Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma. Am J Clin Oncol 2005; 28:107.
- Fujiwara Y, Kiura K, Tabata M, et al. Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anticancer Drugs 2008; 19:431.
- Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2011; 28:1530.
- Strouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 2005; 44:407.
- Walsh A, Kelly DR, Vaid YN, et al. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer 2010; 55:1217.
- Schaeffer EM, Guzzo TJ, Furge KA, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int 2010; 106:62.
- Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22:3720.
- Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol 2006; 24:e14.
- Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655.
- Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966.
- Rafla S. Renal cell carcinoma. Natural history and results of treatment. Cancer 1970; 25:26.
- Finney R. The value of radiotherapy in the treatment of hypernephroma--a clinical trial. Br J Urol 1973; 45:258.
- Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987; 13:665.